Please assess the completion status of the following clinical trial:

Trial Title: Adjuvant Chemotherapy After Preoperative Chemoradiotherapy to Treat Rectal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically confirmed adenocarcinoma of the rectum~2. Patients who treated with preoperative chemoradiation with fluoropyrimidines followed by curative surgery without microscopic residual tumor.~3. AJCC/UICC pathologic stages of ypT3-4 or ypN+~4. Curative surgery not less than 3 and not more than 8 weeks prior to randomization~5. No prior chemotherapy, radiotherapy and immunotherapy except preoperative chemoradiation for rectal cancer~6. ECOG PS 0-1~7. Adequate organ function~8. Informed Consent~Exclusion Criteria:~1. Macroscopic or microscopic evidence of remaining tumor~2. Any histologic feature other than adenocarcinoma or arisen from chronic inflammatory bowel disease~3. More than 8 weeks after curative surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Adjuvant FL (Type: ACTIVE_COMPARATOR): FL (5-FU 380 mg/m2, leucovorin 20 mg/m2 on D1-5 q 4 weeks X 4 cycles)
- Adjuvant FOLFOX (Type: EXPERIMENTAL): FOLFOX (oxaliplatin 85 mg/m2, leucovorin 200 mg/m2 on D1, 5-FU bolus 400 mg/m2 on D1, 5-FU infusion 2400 mg/m2 for 46 hours q 2 weeks X 8 cycles)

Based on this trial design, predict the completion outcome and termination type (if applicable).